Source:http://linkedlifedata.com/resource/pubmed/id/19543243
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0005684,
umls-concept:C0069515,
umls-concept:C0206243,
umls-concept:C0206464,
umls-concept:C0242957,
umls-concept:C0441655,
umls-concept:C0597357,
umls-concept:C0599894,
umls-concept:C0679199,
umls-concept:C0879338,
umls-concept:C0920425,
umls-concept:C1518613,
umls-concept:C1622204,
umls-concept:C1627358,
umls-concept:C2349975
|
pubmed:issue |
1
|
pubmed:dateCreated |
2009-12-16
|
pubmed:abstractText |
The objective of this study was to develop an HER2-targeted, envelope-modified Moloney murine leukemia virus (MoMLV)-based gammaretroviral vector carrying interleukin (IL)-12 gene for bladder cancer therapy. It displayed a chimeric envelope protein containing a single-chain variable fragment (scFv) antibody to the HER2 receptor and carried the mouse IL-12 gene. The fragment of anti-erbB2scFv was constructed into the proline-rich region of the viral envelope of the packaging vector lacking a transmembrane subunit of the carboxyl terminal region of surface subunit. As compared with envelope-unmodified gammaretroviruses, envelope-modified ones had extended viral tropism to human HER2-expressing bladder cancer cell lines, induced apoptosis, and affected cell cycle progression despite lower viral titers. Moreover, animal studies showed that envelope-modified gammaretroviruses carrying IL-12 gene exerted higher antitumor activity in terms of retarding tumor growth and prolonging the survival of tumor-bearing mice than unmodified ones, which were associated with enhanced tumor cell apoptosis as well as increased intratumoral levels of IL-12, interferon-gamma, IL-1beta, and tumor necrosis factor-alpha proteins. Therefore, the antitumor activity of gammaretroviruses carrying the IL-12 gene was enhanced through genetic modification of the envelope targeting HER2 receptor, which may be a promising strategy for bladder cancer therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1476-5500
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
37-48
|
pubmed:meshHeading |
pubmed-meshheading:19543243-Animals,
pubmed-meshheading:19543243-Apoptosis,
pubmed-meshheading:19543243-Cell Line, Tumor,
pubmed-meshheading:19543243-Gene Therapy,
pubmed-meshheading:19543243-Genetic Vectors,
pubmed-meshheading:19543243-Humans,
pubmed-meshheading:19543243-Interleukin-12,
pubmed-meshheading:19543243-Mice,
pubmed-meshheading:19543243-Moloney murine leukemia virus,
pubmed-meshheading:19543243-Oncolytic Virotherapy,
pubmed-meshheading:19543243-Receptor, erbB-2,
pubmed-meshheading:19543243-Transduction, Genetic,
pubmed-meshheading:19543243-Transfection,
pubmed-meshheading:19543243-Urinary Bladder Neoplasms,
pubmed-meshheading:19543243-Viral Tropism
|
pubmed:year |
2010
|
pubmed:articleTitle |
Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy.
|
pubmed:affiliation |
Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan, Taiwan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|